Harrow Health announced that it will release its fourth quarter and full-year 2025 financial results after market close on March 2, 2026, followed by a conference call with investors and analysts on March 3, 2026. The timing allows stakeholders to review the company's annual performance and hear management commentary on operational developments and strategic initiatives.
The company has reaffirmed its 2025 full-year revenue guidance of $270-$280 million, signaling confidence in its financial trajectory for the period. This guidance encompasses revenues from the company's expanding portfolio of pharmaceutical and ophthalmic products.
Harrow continues to broaden its commercial presence across multiple product categories, including VEVYE, IHEEZO, and TRIESENCE. The expanded product lineup reflects the company's strategy to strengthen its market position in specialty pharmaceuticals and enhance revenue diversification across its business segments.